Related Experiment Video
Updated: Mar 15, 2026

Oxygen-Induced Retinopathy Model for Ischemic Retinal Diseases in Rodents
Published on: September 16, 2020
Treatment of Refractory Acute Retinal Necrosis with Intravenous Foscarnet or Cidofovir
Tomasz P Stryjewski1,2, Nathan L Scott2, Miriam B Barshak1,2
1a Massachusetts Eye and Ear Infirmary , Boston , Massachusetts , USA.
Purpose:
To report use of intravenous foscarnet or cidofovir for the treatment of refractory acute retinal necrosis (ARN).
Methods:
Retrospective chart review.
Results:
Four immunocompetent men aged 45-90 years presented with ARN from 2008-2014. One patient with two prior episodes of herpes simplex virus (HSV) ARN developed ARN after 6 years of antiviral prophylaxis. His condition worsened on acyclovir followed by intravenous foscarnet but responded to intravenous cidofovir (final VA in involved eye 20/20). Another patient with HSV ARN had received prolonged acyclovir prophylaxis for HSV keratitis; ARN improved after switching from acyclovir to intravenous foscarnet (final VA 20/125). Two patients with varicella zoster virus (VZV) ARN initially responded to acyclovir but developed fellow eye involvement 2-8 weeks later that worsened on acyclovir but responded to intravenous foscarnet (fellow eye final VA 20/20, 20/40).
Conclusions:
Cases of HSV or VZV ARN that worsen despite intravenous acyclovir treatment may respond to intravenous foscarnet or cidofovir.
Insights
For acute retinal necrosis (ARN) unresponsive to acyclovir, intravenous foscarnet or cidofovir may be effective treatments. These antiviral medications offer hope for patients with refractory herpes simplex virus (HSV) or varicella zoster virus (VZV) ARN.
Area of Science:
- Ophthalmology
- Virology
- Infectious Diseases
Background:
- Acute Retinal Necrosis (ARN) is a severe ocular condition often caused by herpes simplex virus (HSV) or varicella zoster virus (VZV).
- Standard antiviral treatment with acyclovir may be insufficient for refractory cases, necessitating alternative therapeutic strategies.
Observation:
- This study reviewed four immunocompetent male patients diagnosed with ARN between 2008 and 2014.
- Patients presented with ARN despite antiviral prophylaxis or treatment, indicating therapeutic challenges.
Findings:
- One patient with recurrent HSV ARN refractory to acyclovir and foscarnet showed improvement with intravenous cidofovir.
- Two patients with varicella zoster virus (VZV) ARN and one with HSV ARN responded favorably to intravenous foscarnet after initial or worsening disease on acyclovir.
Implications:
- Intravenous foscarnet and cidofovir represent viable treatment options for ARN cases that do not respond to standard acyclovir therapy.
- These findings expand treatment possibilities for severe viral retinitis, potentially improving visual outcomes in challenging cases.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Acute Kidney Injury IV: Diagnostic Studies and Prevention

